Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant icotinib based on ctDNA-MRD after surgery for stage IA EGFR-mutant NSCLC
ChiCTR2400089820Phase 2Not yet recruiting
- Sponsor
- Affiliated Hospital of Jining Medical University
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of icotinib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Affiliated Hospital of Jining Medical University. Primary endpoint: Disease-free survival. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400089820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089820.